Research article · 30 Jul 2026
Conference abstractPublished 31 Aug 2017
Mona Lisa dermal filler
YouGlo, UK
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Since its establishment in 2004, GENOSS has put enormous efforts to become the world’s leading medical device company. The primary mission set forth by GENOSS is to focus on delivering treatment solutions and promoting the well-being of its consumers and patients. GENOSS strives to prepare for a big leap forward into the endless competition of the world’s biotechnology market through its technical innovation. With a considerable portion of sales being spent on Research & Development, and supported by a group of immensely experienced and talented R&D professionals, GENOSS has demonstrated a strong commitment to R&D and to manufacture products with world-beating quality. In addition, GENOSS strictly fulfills and complies with the international quality regulations, including KGMP, ISO 13485 and ISO 9001. Furthermore, the CE mark and the FDA approval on each product confirm its conformity with all of the legal requirements. Mona Lisa dermal filler is new innovative filler with the following properties: 1. Volume effect and retention - the uniform sized hyaluronic acid particles with optimal viscoelasticity can maintain a long-lasting volume. 2. Safe to use on patients âÂ?Â? Mona Lisa is safe to use on patients due to low level of endotoxin and essentially no BDDE residue. 3. Easy procedural operation - the ergonomically-designed rod and grip allow the even distribution of pressure during injection to enable an accurate and safe treatment for both the clinician and the patient. 4. Highly pure hyaluronic acid-GENOSS implements a strict quality control system through direct involvement in the entire production process from the base material of hyaluronic acid to the final product. 5. Global standard quality control - To guarantee the quality of Mona Lisa, GENOSS strictly fulfills and complies with the international quality regulations, including KGMP, ISO 13485 and ISO 9001.
Subjects
DermatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical & Experimental Dermatology Research.
Commentary · 30 Jul 2026
Breaking the Stigma Around Psoriasis: A Broader View of Chronic Skin Disease
Perspective · 28 Jul 2026
Acne as More Than a Cosmetic Concern: A Personal and Medical Perspective
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Experimental Dermatology Research
- SubjectDermatology
- BylineArticles whose byline prints “Maryam Borumand”

